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Abbreviations 
EN2  Engrailed 2 
IgG  Immunoglobulin G 
NY-ESO-1 New York Esophageal Squamous Cell Carcinoma 1 
LREC  Local Research Ethics Committee 
PSA  Prostate Specific Antigen 
LHRH  Luteinizing-hormone-releasing hormone 
CRRPSA  castrate resistant, rising PSA 
BRCA  Breast Cancer 
IMPACT  Identification of Men with a genetic predisposition to Prostate Cancer 
ELISA  enzyme-linked immunosorbent assay 
PBS  Phosphate Buffered Saline 
BSA  Bovine Serum Albumin 
AMACR alpha-Methylacyl-CoA Racemase 
DHFR  Dihydrofolate reductase 
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Summary 
We reported the expression of the homeodomain-containing transcription factor 
Engrailed-2 (EN2) in prostate cancer and showed that the presence of EN2 protein in 
the urine was highly predictive of prostate cancer. This study aimed to determine 
whether patients with prostate cancer have EN2 auto-antibodies, what the prevalence 
of these antibodies is and whether they are associated with disease stage. The 
spontaneous IgG immune response against EN2 and for comparison the tumour 
antigen NY-ESO-1, were tested by ELISA in three different cohorts of prostate cancer 
patients as well as a group of men genetically predisposed to prostate cancer. 32/353 
(9.1%) of the SUN cohort representing all stages of prostate cancer demonstrated EN2 
IgG responses, 12/107 patients (11.2%) in the advanced prostate cancer patients 
showed responses, whilst only 4/121 patients (3.3%) with castrate resistant prostate 
cancer showed EN2 auto-antibodies. No significant responses were found in the 
predisposed group. Anti-EN2 IgG responses were significantly higher in patients with 
prostate cancer compared to healthy control males and similarly prevalent to anti-NY-
ESO-1 responses. Whilst EN2 autoantibodies are not a useful diagnostic or monitoring 
tool EN2 immunogenicity does provide the rationale to pursue studies using EN2 as an 
immunotherapeutic target. 
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Introduction 
Prostate cancer is the most common cancer in men in the UK, accounting for a quarter 
of all new cases of cancer in males [1]. A large proportion of patients with localised 
small volume disease are either cured by treatment or do not require intervention (i.e. 
are managed by active surveillance). There are currently intense worldwide efforts to 
establish reliable biomarkers both for the early detection of prostate cancer and also to 
identify which cancers are likely to progress. We recently reported the diagnostic 
potential of Engrailed-2 (EN2) protein, a homeodomain-containing transcription factor 
secreted into the urine of men with prostate cancer [2]. In a follow-up study we further 
demonstrated that urinary engrailed-2 (EN2) levels predict tumour volume in men 
undergoing radical prostatectomy for prostate cancer [3] and thus may be useful in 
deciding which patients to treat and which to monitor closely. Moreover, tissue 
expression (cytoplasmic, nuclear and membrane) of EN2 was found exclusively in 
prostate cancer and not normal prostatic epithelium in tissue microarrays and patient 
specimens. EN2 was expressed equally at all stages of prostate cancer (T stage 1-4) 
as well as in metastatic disease (lymph nodes) (Morgan personal communication). 
 Antibodies fulfil their adaptive immune response commonly to prevent infection. 
However, the function of tumour-associated autoantibodies, which bind self-antigens 
and have escaped self-tolerance, is generally unknown. Autoantibodies can mediate 
antibody-dependent cell mediated cytotoxicity and complement-dependent cytotoxicity. 
They may also enhance antigen cross-presentation and activation of T lymphocytes.  It 
has been shown that IgG responses to tumour-associated proteins exist in cancer 
patients, making it possible to use human sera to identify immunologically-recognized 
potential tumour antigens [4]. IgG responses to tissue associated antigens may have 
diagnostic value, aid in risk stratification in terms of tumour progression or provide a 
tool for monitoring patients response to treatment. Previous studies have clearly shown 
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a multitude of antibody responses to prostate associated antigens [5-8]. We proposed 
that de novo expression of EN2 in prostate cancer could potentially elicit an 
autoantibody response, and that this could be quantified and potentially used as an 
adjunct to current diagnostic and monitoring biomarkers. 
In this study we assessed the spontaneous antibody response to EN2 in men with 
prostate cancer, both treatment naive at different stages but also patients who had 
received optimal treatment. We detected a significantly higher prevalence of IgG 
responses to EN2 in prostate cancer patients compared to healthy control males, with 
positive antibody responses being found predominantly in patients with higher volume 
and more advanced stage prostate cancer.  
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Materials and Methods 
 
Patient Populations 
The study evaluated blood samples from cancer patients, individuals at high risk of 
developing prostate cancer and healthy volunteer controls. In all cases, written 
informed consent was obtained and the donation of blood samples for autoantibody 
evaluation had received approval by the local ethics committee.  
Our control groups consisted of men who were unlikely to harbour prostate cancer 
based on the absence of symptoms, no family history of cancer, a PSA <2 ng/ml (Av 
age:65; range 40-89). In a similar way, the female controls for the breast and ovarian 
cancer study were women with no past history of any cancer, no symptoms and no 
family history of any malignancy. Patients with histological (on routine biopsy) evidence 
of benign prostatic hypertrophy, prostatic intra-epithelial neoplasia  and prostatitis were 
excluded from the study. These patients have, generally, an abnormal PSA and even 
with saturation biopsies an underlying malignancy cannot be excluded. In the case of 
prostatitis the PSA is often markedly raised, and may remain so for 6-9 months. 
Despite our large cohorts of patients and controls in the study, the total number of 
patients with these 3 conditions would have been too small for meaningful statistical 
comparison. 
 
Blood was taken from prostate cancer patients from the Royal Surrey County Hospital 
(Guildford, UK). We evaluated four specific cohorts: 
(1) Samples from a comprehensive prostate cancer biobank, consisting of the pre-
treatment sample of 353 men with all stages of prostate cancer (SUN cohort) 
LREC: 08/H1306/115.This cohort of patients consisted of men with newly 
diagnosed cancer patients prior to starting any form of treatment. The median 
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age of the cohort was 71 years old, the median PSA at diagnosis was 9 and the 
median Gleason score was 6.  
(2) Patients with rising PSA despite LHRH agonist hormone treatment with normal 
radiological evaluation and no symptoms, designated CRRPSA (castrate 
resistant, rising PSA). This was a cohort of patients recruited to a clinical trial of 
allogeneic whole cell vaccine EUDRACT number 2006-001619-31. The median 
age of the patients was 71, the median PSA was 5.5 and the median Gleason 
score was 7. 
(3) Men with castrate resistant disease with radiological evidence of metastatic 
disease LREC: 08/H1306/115. This was a cohort of patients presenting to 
oncology clinics and receiving chemotherapy. All patients had metastatic 
prostate cancer with either bone or soft tissue disease.  
(4) Patients at high risk of cancer. Samples from the IMPACT cohort (Identification 
of Men with a genetic predisposition to Prostate Cancer: Targeted Screening in 
BRCA1/2 mutation carriers) were used.  To be eligible for this cohort, men had 
to be either a BRCA1 or BRCA2 mutation carrier or from a family harbouring a 
BRCA1/2 mutation but had tested negative themselves (LREC: 05/MRE07/25) 
[9].  
For control comparison of unrelated cancers, we tested two independent female breast 
cancer sample sets of sera taken from women prior to first definitive treatment for their 
breast cancer from Charing Cross Hospital (LREC:07/MRE09/54) and Southampton 
General Hospital (LREC: 05/Q1702/13) [10]. We also evaluated a further control group 
of women with ovarian cancer, at the Royal Surrey County Hospital (LREC: 
09/H1103/50).  Most women had advanced ovarian cancer (FIGO Stage 3c or 4) and 
had received 3 cycles of neoadjuvant chemotherapy prior to their blood test.  In a few 
instances, blood was obtained prior to any treatment. Blood samples from each cohort 
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were taken in accordance with the protocol associated with each study. In all patients, 
sera/plasma was stored in 0.5ml aliquots at −80°C until used for analysis. 
 
Expression of recombinant EN2 and NY-ESO-1 proteins within non-fusion and fusion E 
coli expression vectors. 
EN2 cDNA with optimised codon usage was synthesised and cloned by GenScript, 
USA. This EN2 cDNA was re-cloned into the pQE 31 plasmid (Qiagen, Manchester, 
UK) placing it under the control of a T7 promoter as well as adding aminoterminal 
histidine tag. The NY-ESO-1 cDNA was obtained from pLPCX NY-ESO-1 (a gift from 
Beatrice Yin, Sloan Kettering Institute, NY, USA). To obtain high expression of NY-
ESO-1 protein a fusion partner (mouse dihydrofolate reductase) was needed. To 
achieve this expression, the cDNA of NY-ESO-1 was re-cloned into the pQE 40 
plasmid (Qiagen, Manchester, UK) which resulted in the fusion NY-ESO-1 to the 
carboxyterminal end of mouse dihydrofolate reductase (plus histidine tag). As a non-
specific E coli protein control, mouse dihydrofolate reductase was produced from the 
pQE 40 plasmid containing no insert. All plasmids were transformed into E coli host 
strain (M15 (Qiagen, Manchester, UK) which contain multiple copies of the pREP4 
plasmid which constitutively expresses the lac repressor protein, resulting in regulated 
efficient and controlled expression of E coli proteins. The histidine tags allow 
purification of recombinant proteins by affinity chromatography on Ni-NTA resin 
(Qiagen, Manchester, UK) under denatured conditions.  
ELISA to detect circulating auto-antibodies to EN2 
ELISA MaxiSorp 96-well plates (Nunc, UK) were coated with recombinant EN2, 
NYESO-1 or control DHFR protein produced in E.coli at a concentration of 4ug/well in 
0.1M carbonate buffer (33.5 mM Na2CO3 0.1M NaHCO3, pH9.6) and incubated 
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overnight at 4C. Plates were blocked with 3% BSA/PBS for 2 hours at room 
temperature on a rapid shaker. All washes were performed with PBS/0.1%Tween-20. 
Following 4 washes, plates were incubated with patients and control plasma diluted 
1:100 in 3%BSA/PBS for 1 hour at room temperature on a rapid shaker. All 
plasma/sera were assayed in triplicate. Plates were washed and incubated with goat 
anti-human IgG conjugated to horseradish peroxidase (Jackson ImmunoResearch, UK) 
or mouse anti-human IgG1, IgG2, IgG3 or IgG4-HRP (Life Technologies) in 
3%BSA/PBS for 1 hour on a shaker at room temperature. The plates were then 
incubated with 100l of 3,3’,5,5’-tetramethylbenzidine solution (TMB) (Sigma, UK) for 
colour development. The reaction was stopped by addition of 2M H2SO4. Optical 
density (OD) was measured at 450nm by using a plate reader (Beckman Coulter, UK). 
The mean value plus 3 standard deviations calculated from the test results for healthy 
controls for plasma IgG was used as a cut-off value for evaluation of each assay. This 
ELISA was standardized using rabbit (EN2, Abcam, UK) and goat Abs (NY-ESO-1, 
Lifespan BioSciences, Seattle, WA) with specificity for each of the antigens. 
Immunoblot Analysis 
To confirm ELISA results EN2 detection was performed by running 1g of purified EN2 
protein or the control protein DHFR on a NuPAGE gel followed by semi-dry western 
blotting, blocking using 5% Marvel and chemiluminescent detection. EN2 detection was 
achieved using 1:1000 dilution HRP-conjugated donkey anti-goat IgG (Jackson 
ImmunoResearch, UK). To show that plasma or sera antibodies also recognize our 
recombinant EN2 protein, blots were incubated with patient sera or plasma diluted 
1:100 for 24hrs, washed and detected using HRP conjugated goat anti-human IgG 
(Jackson ImmunoResearch, UK) diluted 1:10,000.  
Statistical Analyses 
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The chi-squared test with a 95% confidence interval was performed using MedCalc to 
evaluate the statistical significance of differences in the proportion of EN2 or NY-ESO-1 
antibody responders between patient cohorts and healthy controls. Differences were 
considered significant when the probability values obtained from the statistical tests 
were 0.05 or less.  
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Results 
 
In order to determine whether circulating EN2-specific antibodies were present in 
patients and healthy controls, an ELISA was developed using recombinant EN2 protein 
produced by expression in E.coli. Samples from patients and healthy controls were 
screened on rEN2 and as a comparison on one of the most immunogenic cancer testis 
antigens, rNY-ESO-1-coated microplates. In addition samples were also screened 
against a non-immunogenic murine protein (DHFR) similarly produced in E.coli to 
eliminate sera/plasma that non-specifically reacted with bacterial contaminants in the 
preparation. Western blotting experiments were performed to verify ELISA results in 
selected patient samples compared to a commercial antibody. The commercial 
antibody only detected a ~45kDa protein in the lane containing the purified 
recombinant EN2 protein (Fig1, goat anti-EN2 Ab, Abcam). Similarly patient sera and 
plasma samples that were shown to be EN2 Ab positive by ELISA also gave a positive 
signal by western blotting (Fig 1, patient 1, 2 and 3)  and conversely those patients that 
were negative for  EN2 Abs by ELISA  gave a negative result by western blotting 
(Figure 1, patient 4 and 5). 
 
Patients with prostate cancer demonstrate spontaneous IgG anti-EN2 responses in 
plasma/serum 
(1) We first evaluated IgG anti-EN2 and anti-NY-ESO-1 autoantibody responses in 
our SUN cohort. These were pre-treatment samples from men with all stages of 
prostate cancer (Fig 2A). To be considered positive for an IgG response the 
cut-off values were calculated as the mean value plus three standard deviations 
from the data pool of the control sera/plasma samples. We found 32/353 (9.1%) 
of the entire SUN cohort taken together as one group demonstrated EN2 IgG 
responses, compared to a 4.8% response to NY-ESO-1. The proportion of EN2 
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IgG responders was significantly different between patients and controls 
(p<0.001). Fig 2B shows titration curves of EN2 antibody-positive and negative 
sera from the SUN cohort. Similar titration curves were also obtained from NY-
ESO-1antibody-positive and negative sera (data not shown). If patients were 
subdivided according to Gleason score or clinical stage, Fig 2C and D, there 
were no significant differences in the proportion of EN2 IgG responders with 
respect to disease stage (T1 to T4 individually) or Gleason score. T4 stage 
patients were not considered statistically because of the low numbers. In 
addition there was also a significant difference in the proportion of NY-ESO-1 
IgG responders from the whole SUN cohort compared to healthy controls 
(p<0.05). However, similar to the EN2 IgG response there were no significant 
differences in the proportion of NY-ESO-1 IgG responders with respect to 
disease stage (T1 to T4 individually) or Gleason score.   
(2) We next evaluated samples from men with a rising PSA level despite optimal 
hormone treatment, but with no disease radiologically (CRRPSA). We found no 
significant increase in the proportion of EN2 IgG responders in this group of 
patients compared to healthy controls. However the proportion of patients within 
this group responding to NY-ESO-1 was statistically different from healthy 
controls (p<0.01) (Fig 3A). 
(3) We found that in men with castrate resistant advanced metastatic disease 
12/107 patients (11.2%) were confirmed as positive for IgG responses to EN2. 
This proportion of EN2 IgG responders was statistically different compared to 
healthy controls (p<0.001). None of these patients were receiving 
chemotherapy at the time the blood was drawn (Fig 3B).  
(4) In men at high risk of developing prostate cancer (IMPACT study participants)  
no significantly increased IgG responses to EN2 or NY-ESO-1 were detected 
compared to the age matched healthy control group (Fig 3C). 
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Of the patients that demonstrated a positive IgG response to EN2 and/or NYESO-1, 
from the SUN study cohort only 2 out of the 47 patients showed a response to both 
antigens, from the CRRPSA cohort none of the Ab positive patients responded to both 
antigens and from the men with castrate resistant disease with radiological evidence of 
metastatic disease only 2 out of 19 patients showed a response to both antigens. 
 
Dominant IgG1 and IgG3 response against EN2 
21 serum/plasma samples reacting with EN2 were additionally subjected to IgG 
subclass testing (IgG subclass 1-4). The level of the IgG subclass of the EN2 antibody 
was determined in each patient using the same ELISA as before but for detection we 
used subclass-specific secondary antibodies. We predominantly found antibodies from 
subclass IgG1 and/or IgG3 in all patients. 11/21 patients tested showed both an IgG1 
and IgG3 response, 9/21 patients gave only an IgG1 response and one patient showed 
only an IgG3 response. No significant IgG2 or IgG4 response was observed in any of 
the patients (Figure 4). 
 
EN2 antibody response remains stable in seropositive patients regardless of treatment 
From the SUN study cohort sequential follow-up samples were available which allowed 
us to study the EN2 autoantibody response in a longitudinal manner. From those 
patients that had demonstrated a positive auto-antibody response to EN2, sequential 
samples were available from 5 patients under active surveillance, 3 patients who had 
received radiotherapy and 5 patients who had received a radical prostatectomy. ELISA 
results on the sequential samples from these patients showed that the antibody 
response remained stable in all but one of these patients regardless of treatment and 
over a period of up to 3 years 11 months. In only one of the patients (SUN 147) who 
had received a radical prostatectomy did the EN2 antibody response fall below the cut-
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off level for positivity following surgery and remained negative for 2 years 10months 
post-surgery (Figure 5). 
 
No significant detection of anti-EN2 IgG responses in female oncological patients 
The assessment of serum/plasma IgG anti-EN2 antibodies in patients with 
malignancies was extended to female patients with breast or ovarian cancer, cancer 
types which we have found to have a high prevalence of EN2 expression at the protein 
level (data not shown). As shown in Figure 6, autoantibody was rarely detected and 
was not higher in patients with breast or ovarian cancer compared to female healthy 
controls. This was in contrast to IgG anti-NY-ESO-1 responses which were clearly 
found in both female cancer groups at a frequency previously published in the literature 
[11]. 
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Discussion 
Serum autoantibodies directed against tumour associated antigens have been 
frequently detected in the sera of patients with different types of cancer [4], including 
prostate cancer. A multitude of autoantibodies to various antigens such as PSA, 
prostatic acid phosphatase, HER-2/neu, p53, glucose-regulated protein 78 and alpha-
Methylacyl-CoA Racemase (AMACR) have been observed in the sera of prostate 
cancer patients [12-15]. Several groups have tried to identify antibody responses to 
such prostate tissue antigens as a means of prostate cancer detection. Maricque et al. 
showed that IgG responses to a panel of commonly recognized prostate antigens were 
as frequently detected in patients with clinical prostatitis as in patients with prostate 
cancer thus demonstrating the need to define those antigens which are clinically 
relevant for prostate cancer [7]. Other studies investigating the antibody responses to 
individual proteins, including huntingtin-interacting protein 1 (HIP1) [16] and alpha-
methylacyl-CoA racemase (AMACR) [15] have shown that antibody responses to these 
proteins are highly specific for prostate cancer. Thus the identification of new 
immunogenic antigens specific for prostate cancer will help to build up a panel of 
commonly recognized prostate cancer antigens that could either be used to detect 
prostate cancer or could be used to evaluate immune responses to the prostate. 
Indeed Smith et al. used a panel of 126 prostate tissue-associated antigens common in 
patients with prostate cancer to investigate whether changes in IgG responses to this 
panel might be used as a measure of immune response, and potentially antigen 
spread, following prostate cancer-directed immune-active therapies [17]. They found 
that different antigens were recognized following androgen deprivation compared with 
vaccine therapies.   
 
In the current study we assessed the levels of auto-antibodies against EN2 in sera from 
patients with prostate cancer, other cancers and from individuals at high risk groups. 
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This is, to our knowledge, the first assessment of spontaneous immune responses to 
EN2 in prostate cancer. We have demonstrated a significant increase in anti-EN2 IgG 
antibodies in patients with prostate cancer as compared to control subjects. 
Furthermore the frequency of anti-EN2 IgG responses in our prostate cancer patient 
cohorts was similar to the number of seropositive patients specific for the highly 
immunogenic tumour antigen, NY-ESO-1. NY-ESO-1 is a cancer/testis antigen which is 
expressed in a number of human cancers including prostate cancer [18]. NY-ESO-1 
appears to be one of the most immunogenic tumour antigens inducing a humoral 
immune response and specific CD8 T-cell reactivity in ~50% of patients with advanced 
NY-ESO-1-expressing tumours [19, 20]. Due to its high immunogenicity and broad 
expression in a variety of cancers, monitoring of antibody responses to NY-ESO-1 has 
already been used as a selection criterion for patients enrolling in NY-ESO-1 cancer 
vaccine trials and as a tool to assess the immunologic and clinical responses of the 
treatment ([19, 20, 21]. Notably an elevated EN2 IgG response was not related to an 
elevated NY-ESO-1 response indicating that a high EN2 response is highly specific 
and not related to a general autoimmune phenomenon. The prevalence of humoral 
immune responses to EN2 within our prostate cancer patient cohorts was similar to 
what has previously been reported in prostate cancer patients for other prostate cancer 
associated proteins (11% PSA and 15.5% Her-2/neu) [12].  
 
We first evaluated pre-treatment sera from men representative of stages 1-4 prostate 
cancer from a prospective biobank.  We found a significant prevalence of IgG 
responses to EN2 in the cancer patients versus controls and this was comparable to 
the response frequency to NY-ESO-1 measured in the same samples. As this group 
contained patients at different stages of prostate cancer we then evaluated whether 
IgG responses to EN2 were more frequent at a particular disease stage. We observed 
no statistical difference in the frequency of EN2 IgG responses between groups of 
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patients based either on Gleason score or T stage. This is in keeping with studies by 
Maricque et al. who also reported that immune responses to multiple antigens were 
detectable as frequently in patients with early stage disease as in patients with 
advanced metastatic disease [7]. 
 
We then went on to test two groups of patients with castrate resistant disease. Here we 
found that there were a significantly lower proportion of EN2 IgG responders in those 
patients with undetectable cancer but a rising PSA (CRRPSA). In contrast the group 
with metastatic disease displayed EN2 IgG responses comparable to the SUN cohort. 
This suggests that detectable disease needs to be present in order for a measurable 
EN2 IgG response to be present. This is further supported by our finding that there 
were no significantly elevated anti-EN2 IgG responses or indeed anti-NY-ESO-1 IgG 
responses in the IMPACT high risk group compared to healthy controls. A number of 
studies have reported that circulating autoantibodies to tumour associated antigens 
have been found to be detectable several years before radiographic detection or 
incidence screening was able to identify the tumours [22-24]. However, the mechanism 
underlying their emergence and regulation of their production is not fully understood. 
Previous reports have described the detection of specific serum autoantibodies in pre-
diagnostic sera and hence their potential use as a screening tool in asymptomatic high 
risk populations [22-24]. Due to the availability of sequential samples from patients 
within the SUN study cohort we were able to address this by performing a longitudinal 
assessment of the EN2 autoantibody response in seropositive patients and the effects 
of different types of treatment on the antibody response. Interestingly in all patients the 
EN2 autoantibody response persisted over the entire sampling period (up to nearly 4 
years in some patients) regardless of the type of treatment received. The only 
exception was one patient who became EN2 sero-negative following radical 
prostatectomy. This finding is perhaps not that surprising as it is known that low-level 
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antibodies can persist up to a life-time in an individual following vaccination or infection. 
This can be attributed to on-going production from a rapid-turnover of memory B-cell 
pools [25] or long-lived plasma cells [26] which can be maintained by antigenic 
stimulation (e.g. persistent antigenic re-exposure) and/or antigen-independent 
activation mechanisms [27]. One can speculate whether the persistence of the 
antibody response is due to low levels of residual tumour or simply due to long-lived 
plasma cells. It is tempting to conclude that the single patient where the antibody 
response disappeared following surgery was actually cured given the stability of the 
antibody levels in the majority of patients studied. However, the persistence of the EN2 
antibody response in most patients precludes its use as a monitoring tool for response 
to treatment. 
 
In this study we went on to further characterize the humoral response to EN2 by 
determining the subclass of antibody induced. It is known that human B cells produce 4 
subclasses of IgG (IgG1, IgG2, IgG3, IgG4), with each subclass having different 
biological functions [28, 29]. The dominant subclasses induced in the antibody 
response against EN2 were IgG1 and IgG3. Although the clinical significance of the 
different IgG1 and IgG3 patterns of response observed in our patients cannot be 
addressed due to the small numbers of patients studied, it is known that the distribution 
of IgG subclasses within an antibody response is affected by a number of factors 
including nature of antigen, dose, route of entry and also the host genotype [30]. This 
was demonstrated in a vaccination study using recombinant CEA where a gradual shift 
from a predominant IgG1 response at 6 months to an IgG4 response at 15 months was 
seen [31]. Similar to our findings the humoral response to NY-ESO-1 has also been 
reported to consist of antibodies of the IgG1 and IgG3 subclass [32]. IgG1 induction 
results from Th1 type CD4 T-cell activation [33], whilst immune-complexes consisting 
of the antigen and IgG1 or IgG3 mainly bind to FcRIIa [34, 35] which is a potent 
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leukocyte activator and stimulates the release of high levels of inflammatory cytokines. 
Thus the induction of IgG1 and IgG3 provide favourable conditions for effector T-cell 
activation in the immune response to EN2. Our group are currently investigating 
cellular immune responses to EN2. 
 
Interestingly the present work showed that the increased anti-EN2 IgG levels appeared 
to be more significant in male cancer patients than in female cancer patients. This was 
in contrast to the auto-antibody response to NY-ESO-1 which was significant in both 
male and female cancer patients. This gender difference in the humoral immune 
response has been reported before and further supports the suggestion that sex 
hormones may significantly affect the humoral immune response to some tumour 
associated antigens [36, 37]. 
 
In summary, this study has shown that the homeodomain-containing transcription 
factor Engrailed-2 (EN2) is immunogenic as evidenced by the significant prevalence of 
IgG responses to EN2 in prostate cancer patients. Antibody immunity to this tumour 
antigen was observed at different stages of the disease. The confirmation of its 
immunogenicity provides the rationale to pursue studies using EN2 as an 
immunotherapeutic target.  
 
Furthermore, our findings may have additional clinical relevance as it is unlikely that 
any single marker for prostate cancer will have the desired high specificity and 
sensitivity for initial diagnosis. Combined analysis of different autoantibodies have 
already increased diagnostic sensitivity and specificity in breast cancer (p53, 
HER2neu, IGFBP-2 and TOPO2a [38] and lung cancer (p53, NY-ESO, CAGE, GBU4-
5, Annexin 1 [39]. Identification of antibodies to further novel tumour associated 
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proteins may thus help build up a ‘panel’ which may also include non-protein 
biomarkers and which in combination may be sufficiently predictive.  
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Titles and legends to figures 
Figure 1. Western blotting experiments for verification of ELISA results shown for 
individual patients. 
The first two lanes denotes the control experiment using a goat anti-EN2 antibody and 
donkey anti-goat IgG-HRP secondary antibody to detect the purified recombinant EN2 
in lane 1 whereas lane 2 that contained the control protein DHFR remained negative. 
Sera from patient 1 and plasma from patients 2 and 3 were EN2 antibody positive in 
ELISA whereas plasma from patients 4 and 5 were negative in ELISA. 
Figure 2. IgG responses to EN2 can be detected in serum of patients with early and 
late stages of prostate cancer. 
Shown are scatter graphs of individual values of serum/plasma immunoglobulin IgG 
anti-EN2 and anti-NY-ESO-1 antibodies tested by enzyme-linked immunosorbent 
assay (ELISA) in patients with prostate cancer (SUN study cohort includes men at all 
stages of prostate cancer, n=353) versus healthy controls (n=214) (A). Serially diluted 
sera from 4 EN2 antibody-positive patients () and sera from 4 healthy volunteers () 
are shown (B). Patients were then grouped according to their combined Gleason score 
(C) or their T stage (1-4) (D). The solid black lines indicate the mean. The blue lines 
indicate the cut-off values calculated as the mean value plus three standard deviations 
from the data pool of the control sera/plasma samples. Values above the cut-off were 
considered as positive. The levels of antibodies against the recombinant proteins EN2 
and NY-ESO-1 are expressed in optical density (OD). The proportion of IgG 
responders to each antigen were compared between patients and healthy controls 
using a chi-squared test. The proportion of patients responding to EN2 and NY-ESO-1 
were found to be statistically different from the healthy controls (p<0.001; *** and 
p<0.05;* respectively). 
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Figure 3. Detectable tumour burden needs to be present in order for a measurable EN2 
IgG response to be present. 
Shown are scatter graphs of individual values of serum/plasma immunoglobulin IgG 
anti-EN2 and anti-NY-ESO-1 antibodies tested by enzyme-linked immunosorbent 
assay (ELISA) in patients with A: castrate resistant disease with rising PSA despite 
LHRH agonist hormone treatment with normal radiological evaluation and no 
symptoms, designated CRRPSA (castrate resistant, rising PSA) LREC (n=121)  , B: 
castrate resistant disease with radiological evidence of metastatic disease (n=107) and 
C: individuals at high risk of cancer (IMPACT cohort) (n=448). In each cohort the 
proportion of EN2 or NY-ESO-1 IgG responders was compared to that found in healthy 
control males. The solid black lines indicate the mean. The blue lines indicate the cut-
off values calculated as the mean value plus three standard deviations from the data 
pool of the control sera/plasma samples. Values above the cut-off were considered as 
positive. The levels of antibodies against the recombinant proteins EN2 and NY-ESO-1 
are expressed in optical density (OD). The proportion of patients responding to each 
antigen was compared between patients and healthy controls using a chi-squared test. 
The proportion of patients responding to NY-ESO-1 within the CRRPSA cohort were 
found to be different from the healthy controls (p<0.01; **) (A). In the castrate resistant 
disease with radiological evidence of metastatic disease group (B) the proportion of 
IgG responders to both EN2 and NY-ESO-1 were  found to be different from healthy 
controls (p<0.001; *** and p<0.05;* respectively). No statistical difference in the 
proportion of IgG responders to either EN2 or NY-ESO-1 were found within individuals 
at high risk of cancer (IMPACT cohort) compared to healthy controls. 
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Figure 4. IgG subclass analysis of EN2 antibody response reveals both IgG1 and IgG3 
responses 
Plasma/sera from EN2 seropositive prostate cancer patients were firstly diluted to 
detect full-length EN2 coated wells in a standard ELISA. After blocking, diluted murine 
monoclonal antibodies specific to various human Ig isotype (IgG1-IgG4) were added to 
determine the Ig subtypes of EN2 specific antibodies in these plasma/sera. 
Representative results are shown from six patients demonstrating different patterns of 
IgG1 and/or IgG3 responses. 
Figure 5. Persistence of EN2 antibody responses in prostate cancer patients 
The longitudinal EN2 antibody response measured by ELISA was determined in EN2 
sero-positive patients. Sera were obtained at various time points over a period ranging 
from 34 to 45 months in different patients. The O.D. value was measured at 
wavelength 450nm. Values obtained with serum dilutions of 1:100 are shown. 
Representative results of this longitudinal assessment of the EN2 autoantibody 
response are shown for patients who were under active surveillance, patients who had 
received radiotherapy and patients who had undergone radical prostatectomy. All 
patients studied remained EN2 seropositive (above the cut-off values calculated as the 
mean value plus three standard deviations from the data pool of the control sera 
samples, blue line) over the time period studied except patient SUN147 who became 
sero-negative following radical prostatectomy. 
Figure 6.  No significant detection of EN2 IgG responses in female oncological patients 
Shown are scatter graphs of individual values of serum/plasma immunoglobulin IgG 
anti-EN2 and anti-NY-ESO-1 antibodies tested by enzyme-linked immunosorbent 
assay (ELISA) in patients with breast cancer (A) or ovarian cancer (B) versus healthy 
sex and age-matched controls. The solid black lines indicate the mean. The blue lines 
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indicate the cut-off values calculated as the mean value plus three standard deviations 
from the data pool of the control sera/plasma samples. Values above the cut-off were 
considered as positive. The levels of antibodies against the recombinant proteins EN2 
and NY-ESO-1 are expressed in optical density (OD). The proportion of IgG 
responders to each antigen were compared between patients and healthy controls 
using a chi-squared test. The proportion of IgG responders to NY-ESO-1 were found to 
be different in both the breast cancer and ovarian cancer patient cohorts compared to 
healthy controls (p<0.001; *** and p<0.01;** for the breast cancer cohorts and 
p<0.001;*** for the ovarian cancer cohort). 
 
 
